Mineral and Bone Disorder Treatment Global Market Report 2024

The global mineral and bone disorder treatment market has grown strongly in recent years. It will grow from $3.06 billion in 2023 to $3.3 billion in 2024 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to chronic kidney disease, aging population, rising awareness of mineral and bone disorders, increased availability of mineral and bone disorder treatments, rising disposable income levels.

The global mineral and bone disorder treatment market is expected to see strong growth in the next few years. It will grow to $4.34 billion in 2028 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to rising demand for quality of life treatments, growing demand for personalized medicine, government spending on healthcare, rising awareness of the importance of early diagnosis. Major trends in the forecast period include advancements in medical research, pharmaceutical developments, digital health, biologic therapies, telehealth and remote monitoring.

The mineral and bone disorder treatment market is poised for growth, driven by the expanding elderly population. This demographic segment comprises individuals aged 65 or older, and they often grapple with issues related to muscle and bone mass decline, resulting in weakened physical strength. To address age-related changes in bones, muscles, and joints, mineral and bone disorder treatments play a crucial role in strengthening bones and slowing down bone loss. As projected by the World Health Organization (WHO), the number of individuals aged 60 or older is anticipated to surge from 1 billion in 2020 to 1.4 billion by 2030 and further to 2.1 billion by 2050. Moreover, the population aged 80 and above is set to triple, growing from 143 million in 2020 to 426 million by 2050. Consequently, the growing elderly population acts as a significant catalyst for the mineral and bone disorder treatment market's expansion.

The rising incidence of chronic kidney diseases is anticipated to drive the growth of the mineral and bone disorder treatment market. Chronic kidney disease (CKD) is characterized by the gradual loss of kidney function over an extended period. Effective treatment of mineral and bone disorders in CKD aims to maintain appropriate mineral balance, preserve bone health, and mitigate the complications associated with these imbalances. As of March 2022, data from the National Library of Medicine, a US-based medical resource, indicates that over 800 million people globally, constituting 10% of the world's population, suffer from chronic kidney disease, a progressive ailment. Consequently, the increasing prevalence of chronic kidney diseases is a key factor propelling the growth of the mineral and bone disorder treatment market.

The limited access to healthcare in specific regions has the potential to impede the market's growth during the forecast period. Patients residing in these areas may encounter various obstacles, including a lack of convenient and affordable transportation, difficulties in taking time off from work, challenges in finding affordable childcare, limited healthcare facility operating hours, and extended waiting times. These barriers can prevent patients from receiving timely and appropriate care for bone and mineral disorders, resulting in adverse health outcomes and potentially reducing the demand for related treatments and products. For example, a survey conducted in December 2021 by the University of Southern California, a US-based public university, found that 30% of Americans reported that high out-of-pocket medical expenses prevented them from seeking treatment. In the United States, approximately 46 million individuals reside in rural areas, often lacking access to necessary healthcare services. As a result, limited healthcare accessibility in specific regions is posing a challenge to the growth of the mineral and bone disorder treatment market.

Prominent companies in the mineral and bone disorder treatment market are strategically focusing on the development and approval of new products to enhance their market position. The increasing prevalence of chronic kidney diseases, particularly among the aging population, has led to the approval of new drugs for mineral and bone disorders. An example of such an approved drug is TYMLOS (abaloparatide), which contains the active drug abaloparatide, a synthetic form of the human parathyroid hormone. For instance, in December 2022, Radius Health Inc., a biopharmaceutical company based in the United States, successfully obtained approval for TYMLOS (abaloparatide). This drug, an analog of parathyroid hormone-related peptide [PTHrP(1-34)], is designed for the treatment of increasing bone density in men with osteoporosis who are at a high risk of fractures. TYMLOS acts as an anabolic agent for bones by selectively activating the parathyroid hormone 1 receptor (PTH1R) expressed in osteoblasts and osteocytes, resulting in enhanced bone formation and density.

In May 2023, Abiogen Pharma Spa, an Italian pharmaceutical company, acquired EffRx Pharmaceuticals SA for $8.77 million. This strategic acquisition of a majority stake in EffRx aligns with Abiogen's growth strategy, serving as a springboard for international expansion and reinforcing its commitment to addressing osteoarticular and bone metabolism diseases. EffRx Pharmaceuticals SA, headquartered in Switzerland, is actively engaged in the treatment of various disorders, including mineral and bone disorders.

Major players in the mineral and bone disorder treatment market are Pfizer Inc., Merck & Co. Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical Co. Ltd., Eli Lilly And Company, Amgen Inc., GlaxoSmithKline PLC, Teva Pharmaceuticals Industries Ltd., Mylan N.V., Daiichi Sankyo Company Limited, Servier Laboratories Pty Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Glenmark Pharmaceuticals Ltd., Alkem Laboratories Ltd., Zydus Cadila Healthcare Ltd., Alembic Pharmaceuticals Limited, Ajanta Pharma Ltd., Abiogen Pharma Spa, Melinta Therapeutics Inc., Intas Pharmaceuticals Ltd., Radius Health Inc., EffRx Pharmaceuticals SA.

North America was the largest region in the mineral and bone disorder treatment market in 2023. The regions covered in mineral and bone disorder treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the mineral and bone disorder treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The key treatments for mineral and bone disorders encompass dietary adjustments, nutritional interventions, medications, the use of supplements, and, in severe cases, dialysis. Dietary modifications involve consuming foods and beverages that promote bone health, reducing the risk of conditions like osteoporosis and mitigating further bone loss. These treatments can be made available through various distribution channels, including hospital pharmacies, online pharmacies, and retail pharmacies, and are tailored to different end users, such as hospitals, homecare settings, specialty clinics, and more.

This report provides mineral and bone disorder treatment market statistics, including mineral and bone disorder treatment industry global market size, regional shares, competitors with a mineral and bone disorder treatment market share, detailed mineral and bone disorder treatment market segments, market trends and opportunities and any further data you may need to thrive in the mineral and bone disorder treatment industry. This mineral and bone disorder treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The mineral and bone disorder treatment market consists of revenues earned by entities by providing services such as treatment planning, patient education and support and multidisciplinary care. The market value includes the value of related goods sold by the service provider or included within the service offering. The mineral and bone disorder treatment market also includes sales of biphosphates, estrogens, phosphate binders, non-calcium, non-metal-based binders, magnesium-based binders, parathyroid hormone therapy, RANKL (receptor activator of nuclear factor kappa-Β ligand) inhibitors and orthopedic implants which are used in providing mineral and bone disorder treatment-related services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.